Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Emcure Pharmaceuticals Ltd. Share Price
Day's Range
Day's Range
Low
₹1,915.10
High
₹2,100.70
Price Summary
| Previous Close | ₹2,003.80 |
|---|---|
| Day's Range | ₹1,915.10 - ₹2,100.70 |
| Open | ₹1,915.90 |
| 52 Week Range | ₹1,260.00 - ₹2,100.70 |
| Volume | 17,44,754 |
| Market Cap | ₹0.04 |
| Previous Close | ₹2,015.75 |
|---|---|
| Day's Range | ₹1,911.95 - ₹2,101.00 |
| Open | ₹1,912.00 |
| 52 Week Range | ₹1,260.10 - ₹2,101.00 |
| Volume | 86,374 |
| Market Cap | ₹0.04 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 34,908.05 |
|---|---|
| Market Cap (₹ in Mn) | 0.04 |
| Dividend Yield(%) | 0.18 |
| Price/Earning (TTM) | 37.81 |
| TTM EPS (₹) | 53.31 |
| P/E Ratio | 32.73 |
| Book Value(₹) | 7.31 |
| PAT Margin (%) | 10.02 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 25.25 |
| Trade Value ( ₹ in Lacs) | 1,737.29 |
|---|---|
| Market Cap (₹ in Mn) | 0.04 |
| Dividend Yield(%) | 0.18 |
| Price/Earning (TTM) | 37.81 |
| TTM EPS (₹) | 53.31 |
| P/E Ratio | 32.73 |
| Book Value(₹) | 7.31 |
| PAT Margin (%) | 10.02 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 25.25 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 10965.73 | 78959.97 |
| Expenses | N/A | N/A |
| PBT | 1656.69 | 9713.49 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 1227.89 | 7074.67 |
About Emcure Pharmaceuticals Ltd.
| Founded | 1981 |
|---|---|
| Managing Director | Satish Mehta |
| NSE Symbol | EMCURE |
Latest News
Emcure Pharmaceuticals informs about acquisition
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘LODR Regulations’) and in furtherance to the disclosure made in the Prospectus filed with the Securities Exchange Board of India, during the Initial Public Offer of the Company, Emcure Pharmaceuticals has informed that Marcan Pharmaceuticals Inc., a subsidiary of the Company (‘Marcan’) has on July 02, 2026 (EDT) entered into share purchase agreements with certain shareholders of Mantra Pharma Inc., a step-down subsidiary of the Company (‘Mantra’), to acquire all of Class E Special Shares in the share capital of Mantra. Consequently, Mantra continues to be 100% subsidiary of Marcan. The particulars of the disclosure required under Regulation 30 and Part A of Schedule III of the LODR Regulations are provided in Annexure A, enclosed.
The above information is a part of company’s filings submitted to BSE.
Centenial Surgical Suture informs about trading window closure
Bharat Parenterals informs about proceedings of AGM
Family Care Hospitals informs about corrigendum to annual report
In continuation of intimation dated September 5, 2026, regarding Notice of the 32nd Annual General Meeting and the Annual Report (AR) for FY 2025-26 of the Family Care Hospital, Family Care Hospitals has informed that a revised version of the Annual Report has been uploaded to the Company’s website. The company has informed that the revision in the AR are only relating to the correction of certain minor typographical / formatting issues and that there are no substantive changes being undertaken to the contents of the AR. The Notice of the 32nd Annual general Meeting and the Annual Report are also being uploaded on the website of the Company at www.familycarehospitals.com.
The above information is a part of company’s filings submitted to BSE.
Concord Biotech informs about board meeting
Pursuant to Regulation 29(1) of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, Concord Biotech has informed that the meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, September 23, 2026 to consider the proposal for declaration of bonus equity shares to the existing equity shareholders of the Company in accordance with the applicable provisions, subject to approval of the shareholders of the Company. Pursuant to Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and Clause 9 of the Code for Prevention of Insider Trading in the securities of the Company, the company has informed that the Trading Window for dealing in the securities of the Company shall remain closed for all designated persons and their immediate relatives from today i.e. September 19, 2026 till 48 hours after the declaration of outcome of Board Meeting. The trading window shall be opened with effect from September 26, 2026.
The above information is a part of company’s filings submitted to BSE.
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Emcure Pharmaceuticals Ltd. is ₹2,003.80 as of 2026-09-18.
The market capitalisation of Emcure Pharmaceuticals Ltd. is ₹38,240.92 as of 2026-09-18.
The 1-year return of Emcure Pharmaceuticals Ltd. is 661.30% as of 2026-09-18.
The P/E ratio of Emcure Pharmaceuticals Ltd. is 32.73 as of 2026-09-21.
The 52-week high and low of Emcure Pharmaceuticals Ltd. are ₹2,100.70 and ₹1,260.00, respectively, as of 2026-09-18.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
